Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women

Menopause

Volumn 17, Issue 4, 2010, Pages 785-790

  Karim, Roksana ^a,b   Stanczyk, Frank Z ^a   Hodis, Howard N ^a,b   Cushman, Mary ^c   Lobo, Roger A ^d   Hwang, Juliana ^b   MacK, Wendy J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d Department of Obstetrics and Gynecology University of Southern California ^*  (United States)

Author keywords

Androgen; C reactive protein; Estrogen; Homocysteine; Soluble intercellular adhesion molecule

Indexed keywords

ANDROSTENEDIONE; C REACTIVE PROTEIN; ESTRADIOL; ESTRONE; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; PRASTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; BIOLOGICAL MARKER; ESTROGEN;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; BLOOD; ESTROGEN THERAPY; MIDDLE AGED;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTRONE; FEMALE; HOMOCYSTEINE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MIDDLE AGED; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 77954951059     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181cc50b2     Document Type: Article

References (38)

1. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
2. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96:4219-4225.
3. Blann AD, McCollum CN. Circulating ICAM-1 in peripheral arterial disease as a predictor of adverse events. Lancet 1998;351:1135.
4. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987; 114:413-419.
5. Oger E, Alhenc-Gelas M, Plu-Bureau G, et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001;101:35-43.
6. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmeno-pausal hormones on inflammation-sensitive proteins: the Postmeno-pausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-722.
7. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893-899.
8. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-1802.
9. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009;151:483-495.
10. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003;107:3165-3169.
11. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
12. Goebelsmann U, Horton R, Mestman JH, et al. Male pseudohermaph-roditism due to testicular 17-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 1973;36:867-879.
13. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17A to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-810.
14. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-58.
15. Goudev A, Georgiev DB, Koycheva N, Manasiev N, Kyurkchiev S. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas 2002;43:49-53.
16. Hodis HN, St John JA, Xiang M, Cushman M, Lobo RA, Mack WJ. Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). Am J Cardiol 2008;101:1131-1133.
17. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17A-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996;98:36-42.
18. Crandall C, Palla S, Reboussin B, et al. Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial. J Womens Health (Larchmt) 2006;15:14-23.
19. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hor-mones and carotid atherosclerosis: a case-control study of the Athero-sclerosis Risk in Communities cohort. Am J Epidemiol 2002;155:437-445.
20. Reinecke H, Bogdanski J, Woltering A, et al. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmeno-pausal women. Am J Cardiol 2002;90:364-368.
21. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003;108: 1688-1693.
22. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2008; 93:131-138.
23. Folsom AR, Golden SH, Boland LL, Szklo M. Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women. Eur J Epidemiol 2005;20:1015-1022.
24. Joffe HV, Ridker PM, Manson JE, Cook NR, Buring JE, Rexrode KM. Sex hormoneYbinding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease. Ann Epidemiol 2006;16:105-112.
25. Sowers MR, Jannausch M, Randolph JF, et al. Androgens are associated with hemostatic and inflammatory factors among women at the mid-life. J Clin Endocrinol Metab 2005;90:6064-6071.
26. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflamma-tion in healthy postmenopausal women. J Clin Endocrinol Metab 2001; 86:4216-4222.
27. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100:1161-1168.
28. McCully KS. Homocysteinemia and arteriosclerosis: failure to isolate homocysteine thiolactone from plasma and lipoproteins. Res Commun Chem Pathol Pharmacol 1989;63:301-304.
29. Silverman MD, Tumuluri RJ, Davis M, Lopez G, Rosenbaum JT, Lelkes PI. Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol 2002;22:587-592.
30. van Aken BE, Jansen J, van Deventer SJ, Reitsma PH. Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cells. Blood Coagul Fibrinolysis 2000;11:159-164.
31. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-218.
32. Barnabei VM, Phillips TM, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health 1999;8:1167-1172.
33. Hsu SC, Liu CM, Long CY, Yang CH, Lee JN, Tsai EM. Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. Fertil Steril 2005;84:1037-1039.
34. Mijatovic V, Kenemans P, Netelenbos C, et al. Postmenopausal oral 17A-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998;69:876-882.
35. Ling S, Dai A, Williams MR, et al. Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology 2002;143:1119-1125.
36. Gutierrez G, Mendoza C, Zapata E, et al. Dehydroepiandrosterone inhibits the TNF-αYinduced inflammatory response in human umbilical vein endothelial cells. Atherosclerosis 2007;190:90-99.
37. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-1342.
38. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.